and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. UTHR sits at a Zacks Rank #3 ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023. [Photo: Brendan ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...